Athira Pharma, Inc. (ATHA) Insider Trading Activity

NASDAQ$6.75
Market Cap
$26.62M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
—
Rank in Industry
—

ATHA Insider Trading Activity

ATHA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$
–
Sells
$
–

Related Transactions

About Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Insider Activity of Athira Pharma, Inc.

Over the last 12 months, insiders at Athira Pharma, Inc. have bought $undefined and sold $undefined worth of Athira Pharma, Inc. stock.

On average, over the past 5 years, insiders at Athira Pharma, Inc. have bought $1.03M and sold $50,439 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 27,400 shares for transaction amount of $66,179 was made by Romano Kelly A (director) on 2024‑06‑24.

List of Insider Buy and Sell Transactions, Athira Pharma, Inc.

2026-01-02Sale
Litton Mark James
President and CEO
2,586
0.0596%
$6.88
$17,792
-5.46%
2026-01-02Sale
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
876
0.0202%
$6.88
$6,027
-5.46%
2026-01-02Sale
Worthington Mark
General Counsel and CCO
876
0.0202%
$6.88
$6,027
-5.46%
2026-01-02Sale
Renninger Robert
Chief Financial Officer
297
0.0068%
$6.88
$2,043
-5.46%
2026-01-02Sale
San Martin Javier
CHIEF MEDICAL OFFICER
1,644
0.0379%
$6.88
$11,311
-5.46%
2025-07-01Sale
Litton Mark James
President and CEO
25,123
0.063%
$0.29
$7,374
+33.67%
2025-07-01Sale
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
8,526
0.0214%
$0.29
$2,502
+33.67%
2025-07-01Sale
Worthington Mark
General Counsel and CCO
8,526
0.0214%
$0.29
$2,502
+33.67%
2025-07-01Sale
Renninger Robert
SVP, Finance and Accounting
2,897
0.0073%
$0.29
$850
+33.67%
2025-07-01Sale
San Martin Javier
CHIEF MEDICAL OFFICER
10,842
0.0272%
$0.29
$3,182
+33.67%
2025-01-02Sale
Litton Mark James
President and CEO
25,107
0.0663%
$0.56
$14,108
-29.55%
2025-01-02Sale
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
8,510
0.0225%
$0.56
$4,782
-29.55%
2025-01-02Sale
Renninger Robert
VP of Finance
2,881
0.0076%
$0.56
$1,619
-29.55%
2025-01-02Sale
Worthington Mark
General Counsel and CCO
8,510
0.0225%
$0.56
$4,782
-29.55%
2025-01-02Sale
San Martin Javier
CHIEF MEDICAL OFFICER
10,826
0.0286%
$0.56
$6,083
-29.55%
2024-09-05Sale
Litton Mark James
President and CEO
5,032
0.0132%
$0.57
$2,848
-26.25%
2024-09-05Sale
Gengos Andrew
CFO and Chief Business Officer
1,272
0.0033%
$0.57
$720
-26.25%
2024-09-05Sale
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
2,525
0.0066%
$0.57
$1,429
-26.25%
2024-09-05Sale
Worthington Mark
GENERAL COUNSEL
2,525
0.0066%
$0.57
$1,429
-26.25%
2024-09-05Sale
Lenington Rachel
COO and CDO
2,525
0.0066%
$0.57
$1,429
-26.25%
Total: 53
*Gray background shows transactions not older than one year

ATHA Institutional Investors: Active Positions

Increased Positions00%00%
Decreased Positions00%00%
New Positions0New0New
Sold Out Positions0Sold Out0Sold Out
Total Postitions00%00%

ATHA Ownership Change vs Market

No data is available at this moment.

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Perceptive Advisors Llc$3,760.0013.51%540,29600%2025-09-30
Bml Capital Management, Llc$2,249.008.08%323,066<10%2025-09-30
Vanguard Group Inc$1,070.003.85%153,789-2<0.01%2025-09-30
Propel Bio Management, Llc$1,039.003.73%149,27900%2025-09-30
Simplify Asset Management Inc.$1,039.003.73%149,27900%2025-09-30
Tang Capital Management Llc$418.001.5%59,998-2<0.01%2025-09-30
Renaissance Technologies Llc$361.001.3%51,924+27,824+115.45%2025-09-30
Acadian Asset Management Llc$280.001.01%40,186-362-0.89%2025-09-30
Pathstone Holdings, Llc$269.000.97%38,606+1,386+3.72%2025-09-30
Blackrock, Inc.$262.000.94%37,643-2<0.01%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.